Anika Therapeutics (ANIK) Net Cash Flow (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Net Cash Flow data on file, last reported at -$16.4 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 321.77% year-over-year to -$16.4 million in Q1 2026; TTM through Mar 2026 was -$12.3 million, a 19.86% increase from a year earlier, with the FY2025 full-year figure at $236000.0, up 101.51% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$16.4 million, down from -$444000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for ANIK reached as high as $5.6 million in Q3 2023 and fell as low as -$16.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$3.1 million across 5 years, with a median of -$3.6 million in 2022.
• Across the five-year window, Net Cash Flow plunged 1433.3% in 2023 and soared 747.91% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$1.4 million in 2022, then jumped by 254.96% to $2.1 million in 2023, then plunged by 337.34% to -$5.1 million in 2024, then jumped by 91.26% to -$444000.0 in 2025, then slumped by 3600.9% to -$16.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$16.4 million in Q1 2026, -$444000.0 in Q4 2025, and $5.1 million in Q3 2025.